Scout Investments Inc. Buys 36,070 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

   2020-10-17 08:10

Scout Investments Inc. boosted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 20.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 211,023 shares of the medical research company’s stock after purchasing an additional 36,070 shares during the period. Scout Investments Inc. owned about 0.19% of NeoGenomics worth $7,785,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of NEO. JPMorgan Chase & Co. lifted its position in NeoGenomics by 29.7% during the first quarter. JPMorgan Chase & Co. now owns 91,812 shares of the medical research company’s stock valued at $2,535,000 after purchasing an additional 21,001 shares during the period. Alliancebernstein L.P. lifted its position in NeoGenomics by 6.7% during the first quarter. Alliancebernstein L.P. now owns 155,850 shares of the medical research company’s stock valued at $4,303,000 after purchasing an additional 9,850 shares during the period. Deutsche Bank AG lifted its position in NeoGenomics by 107.5% during the first quarter. Deutsche Bank AG now owns 277,386 shares of the medical research company’s stock valued at $7,659,000 after purchasing an additional 143,704 shares during the period. Legal & General Group Plc lifted its position in NeoGenomics by 9.5% during the first quarter. Legal & General Group Plc now owns 320,787 shares of the medical research company’s stock valued at $8,867,000 after purchasing an additional 27,730 shares during the period. Finally, Wellington Management Group LLP lifted its position in NeoGenomics by 123.3% during the first quarter. Wellington Management Group LLP now owns 50,682 shares of the medical research company’s stock valued at $1,400,000 after purchasing an additional 27,986 shares during the period. Institutional investors own 91.67% of the company’s stock.



In related news, Director Steven C. Jones sold 10,426 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $36.13, for a total transaction of $376,691.38. Following the completion of the transaction, the director now directly owns 197,932 shares of the company’s stock, valued at $7,151,283.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider George Cardoza sold 82,500 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $39.35, for a total transaction of $3,246,375.00. Following the transaction, the insider now directly owns 433,402 shares of the company’s stock, valued at $17,054,368.70. The disclosure for this sale can be found here. Insiders have sold 538,006 shares of company stock valued at $20,157,671 over the last ninety days. 6.50% of the stock is currently owned by corporate insiders.

Shares of NASDAQ NEO opened at $43.19 on Friday. The firm has a fifty day moving average price of $37.21 and a 200-day moving average price of $32.83. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.79 and a quick ratio of 6.44. The stock has a market cap of $4.77 billion, a PE ratio of -863.80 and a beta of 0.80. NeoGenomics, Inc. has a 1 year low of $19.43 and a 1 year high of $44.58.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 28th. The medical research company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.06. The company had revenue of $86.90 million during the quarter, compared to analysts’ expectations of $86.55 million. NeoGenomics had a negative net margin of 1.33% and a positive return on equity of 0.73%. NeoGenomics’s quarterly revenue was down 14.6% on a year-over-year basis. During the same period last year, the company posted $0.07 earnings per share. On average, research analysts expect that NeoGenomics, Inc. will post -0.01 EPS for the current year.

Several research analysts have weighed in on the stock. Craig Hallum increased their price target on shares of NeoGenomics from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Needham & Company LLC increased their price target on shares of NeoGenomics from $33.00 to $39.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Morgan Stanley assumed coverage on shares of NeoGenomics in a research report on Wednesday, September 9th. They issued an “overweight” rating and a $46.00 price target on the stock. SVB Leerink increased their price target on shares of NeoGenomics from $35.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Finally, Guggenheim assumed coverage on shares of NeoGenomics in a research report on Friday, August 28th. They issued a “buy” rating and a $46.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $37.50.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: Limitations to arbitrage trading

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.


Original Source


CryptoCurrencyUSDChange 1hChange 24hChange 7d
Bitcoin11,711 0.12 % 2.30 % 1.45 %
Ethereum378.81 0.15 % 0.92 % 2.18 %
Tether1.000 0.08 % 0.01 % 0.13 %
XRP0.2453 0.03 % 1.41 % 4.17 %
Bitcoin Cash249.00 0.11 % 0.54 % 3.79 %
Binance Coin30.06 0.55 % 0.69 % 2.02 %
Chainlink10.87 0.30 % 0.94 % 5.25 %
Polkadot3.970 0.07 % 1.83 % 8.10 %
Cardano0.1084 0.14 % 1.47 % 1.25 %
Litecoin48.04 0.22 % 1.94 % 5.13 %
Bitcoin SV159.95 0.06 % 0.41 % 6.01 %
USD Coin0.9999 0.10 % 0.04 % 0.04 %
EOS2.580 0.07 % 1.72 % 2.64 %
Crypto.com Coin0.1096 0.02 % 8.03 % 29.06 %
Monero126.03 0.24 % 2.24 % 3.26 %
TRON0.02573 0.03 % 0.41 % 5.04 %
Stellar0.08556 1.00 % 6.25 % 10.29 %
Tezos2.190 0.06 % 0.62 % 6.78 %
Cosmos5.480 0.38 % 2.11 % 8.44 %
OKB4.590 0.71 % 1.95 % 25.05 %